MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma

Doxorubicin (DOX) is one of the most frequently used anti-cancer drugs and the front line option for hepatocellular carcinoma (HCC) treatment. However, the clinical applications of DOX are restricted largely due to its toxicity and chemoresistance. Here, we report that miR-375 and DOX were co-delive...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Ther Nucleic Acids
Autores principales: Fan, Yin-Ping, Liao, Jia-Zhi, Lu, Ya-Qi, Tian, De-An, Ye, Feng, Zhao, Peng-Xuan, Xiang, Guang-Ya, Tang, Wang-Xian, He, Xing-Xing
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5415965/
https://ncbi.nlm.nih.gov/pubmed/28624193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2017.03.010
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares